189 related articles for article (PubMed ID: 34623418)
1. The impact of smoking cessation on multiple sclerosis disease progression.
Rodgers J; Friede T; Vonberg FW; Constantinescu CS; Coles A; Chataway J; Duddy M; Emsley H; Ford H; Fisniku L; Galea I; Harrower T; Hobart J; Huseyin H; Kipps CM; Marta M; McDonnell GV; McLean B; Pearson OR; Rog D; Schmierer K; Sharrack B; Straukiene A; Wilson HC; Ford DV; Middleton RM; Nicholas R
Brain; 2022 May; 145(4):1368-1378. PubMed ID: 34623418
[TBL] [Abstract][Full Text] [Related]
2. Variability of Multiple Sclerosis Walking Scale and Multiple Sclerosis Impact Scale Scores in People Without Multiple Sclerosis.
Binshalan T; Buckley E; Nair S; Mcneill A
Cureus; 2024 Jan; 16(1):e51811. PubMed ID: 38322083
[TBL] [Abstract][Full Text] [Related]
3. Do depressive and anxiety symptoms influence the construct validity of Multiple Sclerosis Walking Scale-12 scores?
Šilić P; Jones CD; Jeng B; Motl RW
Rehabil Psychol; 2024 May; 69(2):129-134. PubMed ID: 38166293
[TBL] [Abstract][Full Text] [Related]
4. Patient-reported outcomes and survival in multiple sclerosis: A 10-year retrospective cohort study using the Multiple Sclerosis Impact Scale-29.
Raffel J; Wallace A; Gveric D; Reynolds R; Friede T; Nicholas R
PLoS Med; 2017 Jul; 14(7):e1002346. PubMed ID: 28692670
[TBL] [Abstract][Full Text] [Related]
5. Tobacco smoking and disability progression in multiple sclerosis: United Kingdom cohort study.
Manouchehrinia A; Tench CR; Maxted J; Bibani RH; Britton J; Constantinescu CS
Brain; 2013 Jul; 136(Pt 7):2298-304. PubMed ID: 23757766
[TBL] [Abstract][Full Text] [Related]
6. Assessment of Clinically Meaningful Improvements in Self-Reported Walking Ability in Participants with Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III ENHANCE Trial of Prolonged-Release Fampridine.
Hobart J; Ziemssen T; Feys P; Linnebank M; Goodman AD; Farrell R; Hupperts R; Blight AR; Englishby V; McNeill M; Chang I; Lima G; Elkins J;
CNS Drugs; 2019 Jan; 33(1):61-79. PubMed ID: 30535670
[TBL] [Abstract][Full Text] [Related]
7. Erratum.
Mult Scler; 2016 Oct; 22(12):NP9-NP11. PubMed ID: 26041800
[TBL] [Abstract][Full Text] [Related]
8. Prolonged-release fampridine treatment improved subject-reported impact of multiple sclerosis: Item-level analysis of the MSIS-29.
Gasperini C; Hupperts R; Lycke J; Short C; McNeill M; Zhong J; Mehta LR
J Neurol Sci; 2016 Nov; 370():123-131. PubMed ID: 27772740
[TBL] [Abstract][Full Text] [Related]
9. A 12-month prospective, observational study evaluating the impact of disease-modifying treatment on emotional burden in recently-diagnosed multiple sclerosis patients: The POSIDONIA study.
Montanari E; Rottoli M; Maimone D; Confalonieri P; Plewnia K; Frigo M; Francia A; Pala A; Losignore NA; Ragonese P; Veneziano A;
J Neurol Sci; 2016 May; 364():105-9. PubMed ID: 27084226
[TBL] [Abstract][Full Text] [Related]
10. The patient knows best: significant change in the physical component of the Multiple Sclerosis Impact Scale (MSIS-29 physical).
Costelloe L; O'Rourke K; Kearney H; McGuigan C; Gribbin L; Duggan M; Daly L; Tubridy N; Hutchinson M
J Neurol Neurosurg Psychiatry; 2007 Aug; 78(8):841-4. PubMed ID: 17332049
[TBL] [Abstract][Full Text] [Related]
11. Patterns of absolute risk of lung cancer mortality in former smokers.
Halpern MT; Gillespie BW; Warner KE
J Natl Cancer Inst; 1993 Mar; 85(6):457-64. PubMed ID: 8445673
[TBL] [Abstract][Full Text] [Related]
12. The impact of social capital on patients with multiple sclerosis.
Reyes S; Suarez S; Allen-Philbey K; Thomson A; Giovannoni G
Acta Neurol Scand; 2020 Jul; 142(1):58-65. PubMed ID: 32189325
[TBL] [Abstract][Full Text] [Related]
13. The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis.
Ball S; Vickery J; Hobart J; Wright D; Green C; Shearer J; Nunn A; Cano MG; MacManus D; Miller D; Mallik S; Zajicek J
Health Technol Assess; 2015 Feb; 19(12):vii-viii, xxv-xxxi, 1-187. PubMed ID: 25676540
[TBL] [Abstract][Full Text] [Related]
14. Patient-reported outcome parameters and disability worsening in progressive multiple sclerosis.
Abdelhak A; Antweiler K; Kowarik MC; Senel M; Havla J; Zettl UK; Kleiter I; Hoshi MM; Skripuletz T; Haarmann A; Stahmann A; Huss A; Gingele S; Krumbholz M; Selge C; Friede T; Ludolph AC; Overell J; Koendgen H; Clinch S; Wang Q; Ziemann U; Hauser SL; Kümpfel T; Green AJ; Tumani H
Mult Scler Relat Disord; 2024 Jan; 81():105139. PubMed ID: 38000130
[TBL] [Abstract][Full Text] [Related]
15. Validation of the Korean Version of the 12-Item Multiple Sclerosis Walking Scale and Application to Neuromyelitis Optica Spectrum Disorder.
Kim W; Park EY; Hyun JW; Huh SY; Park NY; Jang H; Kim SH; Kim HJ
J Clin Neurol; 2020 Apr; 16(2):270-276. PubMed ID: 32319244
[TBL] [Abstract][Full Text] [Related]
16. [Smoking cessation and bupropion: anxiety and depression as predictors of therapeutic efficacy].
Sampablo Lauro I; Carreras JM; Lores L; Quesada M; Coll F; Sánchez Agudo L
Arch Bronconeumol; 2002 Aug; 38(8):351-5. PubMed ID: 12199915
[TBL] [Abstract][Full Text] [Related]
17. Physical disability, anxiety and depression in people with MS: an internet-based survey via the UK MS Register.
Jones KH; Jones PA; Middleton RM; Ford DV; Tuite-Dalton K; Lockhart-Jones H; Peng J; Lyons RA; John A; Noble JG
PLoS One; 2014; 9(8):e104604. PubMed ID: 25153835
[TBL] [Abstract][Full Text] [Related]
18. Psychometric properties of the Croatian version of the Multiple Sclerosis Walking Scale (MSWS-12).
Jerković A; Nikolić Ivanišević M; Šimić N; Poljičanin A; Đogaš Z; Rogić Vidaković M
Disabil Rehabil; 2023 Oct; 45(20):3373-3378. PubMed ID: 36222552
[TBL] [Abstract][Full Text] [Related]
19. The physical and psychological impact of multiple sclerosis using the MSIS-29 via the web portal of the UK MS Register.
Jones KH; Ford DV; Jones PA; John A; Middleton RM; Lockhart-Jones H; Peng J; Osborne LA; Noble JG
PLoS One; 2013; 8(1):e55422. PubMed ID: 23383186
[TBL] [Abstract][Full Text] [Related]
20. Fatigue, Depression, and Anxiety Among Ambulating Multiple Sclerosis Patients.
AlSaeed S; Aljouee T; Alkhawajah NM; Alarieh R; AlGarni H; Aljarallah S; Ayyash M; Abu-Shaheen A
Front Immunol; 2022; 13():844461. PubMed ID: 35422797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
